Cerenis Therapeutics receives 2.5 Million euro investment

Printer Print Email Email
Toulouse: Cerenis Therapeutics, a privately held pharmaceutical company, has received a 2.5 million euro investment to finance ongoing clinical development of its portfolio of HDL related products for the treatment of cardiovascular and metabolic diseases. The funds were granted by OSEO, a French public holding company that provides financial support to promising French companies. The financing will support continued development of the company's CER-001 program (recombinant HDL). In 2008 the company initiated preclinical studies to enable an Investigational New Drug (IND) application for this product candidate. "This new source of funding will support our efforts to advance Cerenis HDL through the IND process and onto clinical development," said Jean-Louis Dasseux, President and CEO of Cerenis. Founded in 2005, OSEO's mission is to support the most innovative and promising small and medium enterprises and very small enterprises based in France.